Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Vaccines01:30

Cancer Vaccines

939
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
939
Tumor Immunotherapy01:27

Tumor Immunotherapy

1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Brain targeting and trafficking of extracellular vesicles in central nervous system diseases: a therapeutic roadmap.

Nanomedicine (London, England)·2026
Same author

Structure and mechanism of the HSV-1 origin-binding protein UL9.

Journal of virology·2026
Same author

Growth Dynamics of selected Vibrio spp. in mono-, co-culture and multi-bacterial microcosms: Investigating the prevalence of Vibrio parahaemolyticus in seawater.

Marine environmental research·2026
Same author

Collagen nanofiber reinforced alginate hydrogel tube microbioreactors for cell culture.

Frontiers in bioengineering and biotechnology·2026
Same author

The intravenous targeted nanopeptide, CAQK, is neuroprotective and improves motor function after spinal cord injury in rats.

The journal of trauma and acute care surgery·2026
Same author

A Phase I trial of PLZ4-coated paclitaxel-loaded micelles in patients with refractory non-muscle-invasive bladder cancer.

Nanomedicine (London, England)·2026

Related Experiment Video

Updated: Jan 12, 2026

Preparation, Characteristics, Toxicity, and Efficacy Evaluation of the Nasal Self-Assembled Nanoemulsion Tumor Vaccine In Vitro and In Vivo
07:33

Preparation, Characteristics, Toxicity, and Efficacy Evaluation of the Nasal Self-Assembled Nanoemulsion Tumor Vaccine In Vitro and In Vivo

Published on: September 28, 2022

2.2K

Designing Programmable Peptide Nucleic Acid-based Nanovaccines for Anticancer Immune Activation.

Yanyu Huang1, Cuiqing Huang2, Sakshi Pandita1

  • 1Department of Biochemistry and Molecular Medicine, University of California, Davis, Sacramento, CA, 95817, USA.

Small (Weinheim an Der Bergstrasse, Germany)
|November 7, 2025
PubMed
Summary

A novel peptide nucleic acid vaccine nanoplatform (PVN) effectively targets cancer cells and immune cells, enhancing anti-tumor responses. This programmable platform shows significant tumor regression and prolonged survival in melanoma models.

Keywords:
cancer immunotherapydendritic cellsmelanomananovaccinepeptide nucleic acid

More Related Videos

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
11:58

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

8.0K
Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
10:18

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

1.7K

Related Experiment Videos

Last Updated: Jan 12, 2026

Preparation, Characteristics, Toxicity, and Efficacy Evaluation of the Nasal Self-Assembled Nanoemulsion Tumor Vaccine In Vitro and In Vivo
07:33

Preparation, Characteristics, Toxicity, and Efficacy Evaluation of the Nasal Self-Assembled Nanoemulsion Tumor Vaccine In Vitro and In Vivo

Published on: September 28, 2022

2.2K
Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
11:58

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

8.0K
Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
10:18

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

1.7K

Area of Science:

  • Biotechnology and Nanomedicine
  • Immunology and Cancer Research

Background:

  • Developing cancer vaccines that deliver antigens and adjuvants to immune cells without causing excessive inflammation is a significant hurdle.
  • Targeted delivery systems are crucial for enhancing vaccine efficacy and minimizing off-target effects in cancer immunotherapy.

Purpose of the Study:

  • To develop and evaluate a versatile peptide nucleic acid (PNA)-based vaccine nanoplatform (PVN) for robust anti-tumor immune responses.
  • To investigate the targeting capabilities and immune-stimulating properties of the PVN in a syngeneic melanoma model.

Main Methods:

  • Constructed a PNA-based vaccine nanoplatform (PVN) using an 11-mer PNA scaffold for one-pot loading of antigenic peptide (SIINFEKL), CpG adjuvant, and LLP2A targeting ligand.
  • Utilized super-resolution fluorescence imaging and circular dichroism spectroscopy to analyze the nanoplatform's structure and component interactions.
  • Assessed anti-tumor efficacy in a B16-OVA syngeneic melanoma mouse model, evaluating immune cell responses and tumor regression.

Main Results:

  • The PVN successfully co-loaded antigenic peptide, adjuvant, and targeting ligand, demonstrating specific spatial arrangement and PNA strand binding.
  • The LLP2A ligand on PVNs targeted activated α4β1 integrin on immune and melanoma cells, enhancing antigen presentation by dendritic cells.
  • PVN treatment significantly boosted CD8+ T cell and natural killer cell responses, leading to substantial tumor regression and prolonged survival in mice.

Conclusions:

  • The PNA-based vaccine nanoplatform (PVN) is a highly versatile and programmable system for eliciting potent anti-tumor immunity.
  • The modular design allows for the convenient assembly of various components, making PVN a practical platform for personalized cancer vaccine development.
  • PVN demonstrates significant potential for advancing cancer vaccine strategies through targeted delivery and enhanced immune stimulation.